Prof. Dr. Kai Deusch
Dr. Deusch has more than 30 years experience in Healthcare. During the past 15 years he has been engaged in supporting start-up, growth and mid-sized companies as an investor, management consultant and entrepreneur with a focus on Medtech, Biotech, diagnostics and care provision services. He is the founder and sole owner of Medicis Capital, an investment boutique with focus on the EU, the US and Asia providing funds, M&A advisory services, management resources and strategic advice for growth stage companies. Medicis currently holds a portfolio of investments in Europe and the US and is actively supporting the growth of highly innovative companies. Prior to building Medicis he has been the CEO of a biomaterials firm, a partner in a global IP licensing and –litigation firm, a Partner/Director responsible for Healthcare transactions in the DACH countries at APAX Partners, a leading global private equity firm and a manager at McKinsey & Company. He had a longstanding medical career and has been a Professor in Internal Medicine and Immunology/Oncology with the Medical Faculty of Technical University Munich, a researcher and clinician at the Dana Farber Cancer Center, Harvard Medical School and the Division of Hematology/Oncology at Tufts University. He is a board certified internist, hold an M.D and PhD. from the University of Mainz (Germany) and a B.Sc. in Biology from the University of Minnesota, Minneapolis.
President, Chief Executive Officer and Director
Steve has been at NuvoLase Inc. since September 2011. Steven has more than 20 + years of experience in the light-based technology field and aesthetic industry. From 1999 – 2003 Steven served as the Director of Global Marketing at Cutera, Inc. (formally Altus Medical), a provider of laser and other light-based and aesthetic treatment systems. Prior to joining Cutera, Steven spent over ten years at Coherent Medical, Inc. (a manufacturer of laser, optics and related equipment) in senior executive roles in sales, marketing and new business development. Steven also held management positions in Fortune 500 Companies including Johnson and Johnson, Ethicon and 3M Health Care.
John F. Rousseau, Jr.
John has over 30 years of experience in investment management, corporate operations and legal practice. He has been active in guiding a variety of companies, as board member, investor and counsel, in all stages from start-up to being public. He has led investments in a variety of healthcare companies focused in the fields of medical devices, biotechnology, diagnostics, medical instruments and healthcare services. He is co-founder of Nexus Medical Technology & Capital, a private equity firm specializing in medical technology and life science investments in the US and Europe. Earlier in his career, John held the operating positions of Senior Vice President, Homart Development (a Sears Roebuck subsidiary), and Senior Vice President, Spaulding & Slye Company. Prior to beginning his business career, he practiced law for fifteen years with firms in New York, Geneva and Boston, where he was a Senior Partner with the law firm of Hale & Dorr (now Wilmer Hale). John holds a B.A. from Amherst College and a J.D. from Columbia Law School.
Edwin Snape, PhD
Dr. Snape has over 35 years’ experience of founding, investing in and guiding the development of more than 40 public and private healthcare and speciality materials companies. He was a co-founder of the Liposome Company, which was sold to Élan Corporation for over $700 million, and Ergenics, a pioneer in power applications of metal hydrides. Dr.Snape is a PhD metallurgist, co-founder of Nexus Medical and Technology Capital, a private equity firm specializing in medical technology and life science investments in the US and Europe, and has wide-ranging experience of technologies and their application to healthcare needs around the world. Prior to Nexus, Ed was Managing General Partner of The Vista Group, a leading east coast venture capital firm; Chairman of Orien Ventures, a private equity firm with Pacific Rim affiliations; and a Director of the Cygnus Funds, two U.K.-based private equity firms specializing in European investments.